AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BOTANIX PHARMACEUTICALS LTD

0.112

+0.0021.82%

Volume:2.85M

Turnover:325.08K

Market Cap:221.23M

PE:-2.39

High:0.120

Open:0.110

Low:0.110

Close:0.110

52wk High:0.535

52wk Low:0.100

Shares:1.98B

Float Shares:1.72B

Volume Ratio:0.82

T/O Rate:0.17%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.047

EPS(LYR):-0.047

ROE:-90.93%

ROA:-42.91%

PB:2.72

PE(LYR):-2.39

Loading ...

Overview Company News Filings

Blue Ocean Technologies Announces Executive Changes

NetAssist Strengthens SOC Capabilities with Graylog Security

Indonesia Joins Nexus Project to Strengthen Cross-Border Payments

Botanix Pharmaceuticals Hosts Quarterly Update Webinar

ASX Penny Stocks Spotlight: Botanix Pharmaceuticals And Two More Promising Picks

Simply Wall St.

Botanix Pharmaceuticals Buys Back Nearly 7 Million Ordinary Shares

MT Newswires Live

David Allen reveals the systematic playbook behind Plato’s 25 percent returns

Botanix Pharmaceuticals Shareholders Reject Remuneration Report

MT Newswires Live

Botanix Pharmaceuticals Showcases Sofdra Clinical Data at Dermatology Conferences

Will Botanix Pharmaceuticals’ (ASX:BOT) Investor Outreach Reinforce Management Credibility or Raise Fresh Questions?

Simply Wall St.

Botanix Pharmaceuticals (ASX:BOT): Evaluating Valuation Following Leadership Changes, Product Rollouts, and Conference Updates

Simply Wall St.

Did Sofdra Launch Progress and a Leadership Change Just Shift Botanix Pharmaceuticals' (ASX:BOT) Investment Narrative?

Simply Wall St.

Botanix Pharmaceuticals to Not Rely Upon ASX Partial Waiver After Verifying Sufficient Securities Under its Placement Capacity

MT Newswires Live

Botanix Pharmaceuticals Back On Track With Reduced Cash Burn, Euroz Hartleys Says

MT Newswires Live

Botanix Pharmaceuticals Q1 Net Revenue Hits $7.1 Million as Sofdra Prescriptions Jump 50%

Botanix Pharmaceuticals Ltd - Sofdra Net Revenue to a$7.1 Mln in Q1 FY26

THOMSON REUTERS

While Botanix Pharmaceuticals (ASX:BOT) shareholders have made 123% in 3 years, increasing losses might now be front of mind as stock sheds 12% this week

Simply Wall St.

What a 40% Year Taught Us: 4 Lessons from the past 12 months (and 3 new stocks to buy)

Botanix Pharmaceuticals' Sofdra Topical Gel Dermatologists' Preferred Option for Hyperhidrosis Treatment in Survey, Euroz Hartleys Says

MT Newswires Live

Hyperbot (BOT) has surged over 34% in the last 24 hours, currently trading at $0.175

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BOT.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BOT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BOT.AU\",,,,,undefined,":{"symbol":"BOT.AU","market":"AU","secType":"STK","nameCN":"BOTANIX PHARMACEUTICALS LTD","latestPrice":0.112,"timestamp":1770868174602,"preClose":0.11,"halted":0,"volume":2846602,"delay":0,"changeRate":0.0181818181818182,"nameEN":"BOTANIX PHARMACEUTICALS LTD","floatShares":1717605114,"shares":1975259977,"eps":-0.046827,"marketStatus":"Trading","change":0.002,"latestTime":"02-12 14:51:02 AEDT","open":0.11,"high":0.12,"low":0.11,"amount":325082,"amplitude":0.090909,"askPrice":0.115,"askSize":639833,"bidPrice":0.11,"bidSize":2777723,"shortable":3,"etf":0,"ttmEps":-0.046827,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770872400000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.11,"openAndCloseTimeList":[[1770850800000,1770872400000]],"volumeRatio":0.815543,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BOT.AU\",,,,,undefined,":{"symbol":"BOT.AU","floatShares":1717605114,"roa":"-42.91%","roe":"-90.93%","lyrEps":-0.046827,"volumeRatio":0.815543,"shares":1975259977,"dividePrice":0,"high":0.12,"amplitude":0.090909,"preClose":0.11,"low":0.11,"week52Low":0.1,"pbRate":"2.72","psRate":"38.21","week52High":0.535,"institutionHeld":0,"latestPrice":0.112,"committee":0.625561,"eps":-0.046827,"divideRate":0,"volume":2846602,"delay":0,"ttmEps":-0.046827,"open":0.11,"prevYearClose":0.135,"prevWeekClose":0.12,"prevMonthClose":0.11,"prevQuarterClose":0.135,"fiveDayClose":0.12,"twentyDayClose":0.135,"sixtyDayClose":0.13},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BOT.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BOT.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BOT.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610655881","title":"Blue Ocean Technologies Announces Executive Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2610655881","media":"prnewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610655881?lang=en_us&edition=fundamental","pubTime":"2026-02-09 21:30","pubTimestamp":1770643800,"startTime":"0","endTime":"0","summary":"Appoints Robert Virgilio as Chief Compliance Officer of Blue Ocean ATS & Expands South Korean Team with Addition of Daehyun Kim in new Trade Support Role. Virgilio holds a Bachelor of Science from Niagara University, an MBA from St. John's University, and FINRA Series 4, 7, 9/10, 14, 24, and 57 licenses. He is a past member of the SIFMA Self-Regulation and Supervisory Practices Committee, and NYSE Market Compliance Advisory Committee. Kim holds a Master of Commerce  from the University of Sydney and a Bachelor's/Diploma in Information Technology from Queensland University of Technology. He is a Certified Securities and Derivatives Investment Advisor (Korea Financial Inv","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/blue-ocean-technologies-announces-executive-changes-302681886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOT.AU","NMS","BK7096","BK4161","BK7508","BK7502","ATS"],"gpt_icon":0},{"id":"2610755505","title":"NetAssist Strengthens SOC Capabilities with Graylog Security","url":"https://stock-news.laohu8.com/highlight/detail?id=2610755505","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610755505?lang=en_us&edition=fundamental","pubTime":"2026-02-09 08:00","pubTimestamp":1770595200,"startTime":"0","endTime":"0","summary":"Delivers Faster Detection and Scalable Operations for Enterprise Customers in Regulated Industries. PETALING JAYA, Malaysia and HOUSTON, Feb. 8, 2026 /PRNewswire/ --NetAssist  Sdn Bhd, a leading Managed Security Services Provider , today announced it has enhanced its security operations using Graylog Security, a modern SIEM platform built to remove the barriers that slow security teams. The deployment enables NetAssist to improve threat detection speed, scale log data processing, and increase operational efficiency for its customers in critical infrastructure, banking, and national payment networks.\"As customer security environments grow more complex, we prioritize technologies that allow us to provide holistic cyber resilience, and through our SOCs, to respond rapidly, scale securely, and deliver outcomes with consistency,\" said Hon Fun Ping, Managing Director of NetAssist. \"Graylog gives us the performance and flexibility to do just that, without compromising on visibility or cost.\".","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/netassist-strengthens-soc-capabilities-with-graylog-security-302681754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7061","BK7508","BK4588","SOC.AU","BK7502","BK4103","BK4213","SOC","BK4220","BK4585","BOT.AU","BK7096"],"gpt_icon":0},{"id":"2608841942","title":"Indonesia Joins Nexus Project to Strengthen Cross-Border Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2608841942","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608841942?lang=en_us&edition=fundamental","pubTime":"2026-02-03 11:36","pubTimestamp":1770089771,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta-Bank Indonesia  has joined the Nexus project initiated by the Bank for International Settlements , signifying the central bank's commitment to enhance the connectivity of cross-border payment systems.Bank Indonesia will play a role in preparing and implementing the Nexus along with five central banking partners: Bank Negara Malaysia , Bangko Sentral ng Pilipinas , Monetary Authority of Singapore , Bank of Thailand , and Reserve Bank of India .BI Governor Perry Warjiyosaid Indonesia's participation in Nexus serves as a strategic move to provide efficient and affordable cross-border payment solutions for Indonesian people and businesses.","market":"sg","thumbnail":"https://statik.tempo.co/data/2025/11/29/id_1444271/1444271_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2025/11/29/id_1444271/1444271_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2084658/indonesia-joins-nexus-project-to-strengthen-cross-border-payments","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2084658/indonesia-joins-nexus-project-to-strengthen-cross-border-payments","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["LU2413665964.HKD","IPS","BIS","MAS","BK7508","BK4585","SG9999001440.SGD","BK4588","LU2413666004.HKD","BK7096","BK7129","BK7502","LU1721427968.SGD","BOT.AU","LU1596574779.USD","LU0170899867.USD","LU1165135440.EUR","LU1620156130.USD","BIS.AU","BK4086","LU1620156213.USD","LU1543694498.USD"],"gpt_icon":0},{"id":"2605594394","title":"Botanix Pharmaceuticals Hosts Quarterly Update Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2605594394","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605594394?lang=en_us&edition=fundamental","pubTime":"2026-01-22 12:12","pubTimestamp":1769055174,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals Ltd. will host a Quarterly Update Webinar on Tuesday, 27 January. The event will feature the executive team presenting the Company's Quarterly Activity Report and 4C Quarterly Cash Flow Report. Pre-registration is required for participants.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Botanix Pharmaceuticals Ltd. published the original content used to generate this news brief on January 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL4rPjrH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7096","BOT.AU","BK7502"],"gpt_icon":0},{"id":"2595281087","title":"ASX Penny Stocks Spotlight: Botanix Pharmaceuticals And Two More Promising Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2595281087","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595281087?lang=en_us&edition=fundamental","pubTime":"2025-12-31 10:05","pubTimestamp":1767146710,"startTime":"0","endTime":"0","summary":"As the Australian market approaches the holiday season, it seems to be winding down with a slight dip of 0.2%, largely attributed to profit-taking as major Wall Street indices near all-time highs. Despite this quiet period, investors may find intriguing opportunities in penny stocks, a term that might seem outdated but still signifies potential growth avenues in smaller or emerging companies. These stocks can offer significant returns when backed by strong financials; let's explore three such...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice1-main-header/1585186836557","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice1-main-header/1585186836557"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-vys/vysarn-shares/news/asx-penny-stocks-spotlight-botanix-pharmaceuticals-and-two-m-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-vys/vysarn-shares/news/asx-penny-stocks-spotlight-botanix-pharmaceuticals-and-two-m-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7506","AAL.AU","BK7132","BK7095","EDU.AU","BK7045","BK7096","BK7508","BK7048","BK7094","MXI.AU","DSK.AU","BK7050","SSM.AU","BK7055","BK7111","BK7143","BK7502","VRS.AU","MTO.AU","VYS.AU","BOT.AU","IGL.AU","BK7077","EZZ.AU","ONE.AU","BK7128","WAF.AU","BK7104"],"gpt_icon":0},{"id":"2595753139","title":"Botanix Pharmaceuticals Buys Back Nearly 7 Million Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2595753139","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595753139?lang=en_us&edition=fundamental","pubTime":"2025-12-30 05:49","pubTimestamp":1767044955,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals (ASX:BOT) repurchased 6.9 million ordinary, fully-paid shares in an employee share scheme buyback on Monday, according to a Tuesday filing with the Australian bourse.The company did not pay consideration to buy back these shares as it was issued erroneously, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7502","BK7096","BOT.AU","BK7508"],"gpt_icon":0},{"id":"2585082162","title":"David Allen reveals the systematic playbook behind Plato’s 25 percent returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2585082162","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585082162?lang=en_us&edition=fundamental","pubTime":"2025-11-21 09:51","pubTimestamp":1763689870,"startTime":"0","endTime":"0","summary":"Investors love a good story about instinct. The great stock picker who can “feel” when something is about to break higher. The seasoned operator who claims to smell risk before it hits the screens.His edge comes from something far less romantic and far more scalable, a systematic process that can sift through more than 11,000 global companies, flag risks early, and uncover opportunities across growth, value and quality. The results are hard to ignore, since launching in September 2021, the Plato Global Alpha Fund has returned 25 percent per annum, placing it among the best performers in its class.Allen’s philosophy starts with scale. While the MSCI World Index contains roughly 1,300 companies, his investable universe spans more than 11,500. The fund currently holds around 970 long positions and 470 shorts. That sounds like the opposite of traditional stock picking, but scale is an essential ingredient.Some of the fund’s best work comes on the short side, and it is anchored in one eye-c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/david-allen-reveals-the-systematic-playbook-behind-plato-s-25-percent-returns","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/david-allen-reveals-the-systematic-playbook-behind-plato-s-25-percent-returns","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK4207","LU2505996681.GBP","IE0034235303.USD","LU0238689110.USD","LU1162221912.USD","BK7502","LU0265550359.USD","IE00BDCRKT87.USD","LU0211328371.USD","LU0070302665.USD","IE00BLSP4239.USD","LU0345769128.USD","LU1629891620.HKD","LU2237443978.SGD","LU1894683264.USD","LU0942090050.USD","LU0787776722.HKD","LU2054465674.USD","IE00B1BXHZ80.USD","LU1145028129.USD","LU1496350171.SGD","LU0211327993.USD","LU0971096721.USD","BOT.AU","IE00BYXW3230.USD","LU2237443549.SGD","BK4504","LU0256863811.USD","LU2242649171.HKD","LU2211815571.USD","LU2462157665.USD","LU0170899867.USD","BOE.AU","IE00BDRTCR15.USD","LU2023250843.SGD","LU0211326839.USD","LU2264538146.SGD","LU2381873111.SGD","LU1267930490.SGD","LU0251132253.USD","BK4588","LU1496350502.SGD","IE00B3S45H60.SGD","PGA1.AU","CBA.AU","LU2592432038.USD","BK4516","LU1032466523.USD","LU0265550946.USD","LU1988902786.USD"],"gpt_icon":0},{"id":"2584901419","title":"Botanix Pharmaceuticals Shareholders Reject Remuneration Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2584901419","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584901419?lang=en_us&edition=fundamental","pubTime":"2025-11-20 12:04","pubTimestamp":1763611462,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals'  shareholders rejected its remuneration report at its annual general meeting on Thursday, according to a same-day Australian bourse filing.Over 73% of the votes cast at the meeting were against the remuneration report.The company's shares rose nearly 2% in recent trading on Thursday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","BK7508","BK7502","BK7096","BOT.AU","XAO.AU","XJO.AU"],"gpt_icon":0},{"id":"2582556812","title":"Botanix Pharmaceuticals Showcases Sofdra Clinical Data at Dermatology Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2582556812","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582556812?lang=en_us&edition=fundamental","pubTime":"2025-11-10 09:12","pubTimestamp":1762737162,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals Ltd. recently announced that three scientific posters related to Sofdra were accepted and exhibited at major dermatology continuing medical education  conferences in October and early November 2025. The posters presented scientific findings to dermatology professionals at these events.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Botanix Pharmaceuticals Ltd. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLbKhq59:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BOT.AU","BK7096","BK7502"],"gpt_icon":0},{"id":"2579186920","title":"Will Botanix Pharmaceuticals’ (ASX:BOT) Investor Outreach Reinforce Management Credibility or Raise Fresh Questions?","url":"https://stock-news.laohu8.com/highlight/detail?id=2579186920","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579186920?lang=en_us&edition=fundamental","pubTime":"2025-10-29 22:40","pubTimestamp":1761748801,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals recently held a special call to update investors on its quarterly activity report and Sofdra® topical gel launch, and is set to present at the 2025 Canaccord Genuity Drug & Device Conference with CEO Howie McKibbon as speaker.\nThese events highlight the company's efforts to communicate operational progress and product momentum to the market at key industry forums.\nWe’ll explore how management’s proactive communication on the Sofdra launch is shaping Botanix...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-bot/botanix-pharmaceuticals-shares/news/will-botanix-pharmaceuticals-asxbot-investor-outreach-reinfo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-bot/botanix-pharmaceuticals-shares/news/will-botanix-pharmaceuticals-asxbot-investor-outreach-reinfo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BOT.AU","BK7508","BK7502","BK7096"],"gpt_icon":0},{"id":"2577877145","title":"Botanix Pharmaceuticals (ASX:BOT): Evaluating Valuation Following Leadership Changes, Product Rollouts, and Conference Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2577877145","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577877145?lang=en_us&edition=fundamental","pubTime":"2025-10-24 01:28","pubTimestamp":1761240491,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals (ASX:BOT) is drawing fresh attention this month as the company prepares for a major conference appearance, has updated investors on recent performance and product rollouts, and introduced a new joint company secretary to its leadership team.\nSee our latest analysis for Botanix Pharmaceuticals.\nAfter a series of notable updates, including the appointment of a seasoned company secretary and an upcoming presentation at the Canaccord Genuity Drug & Device Conference,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-bot/botanix-pharmaceuticals-shares/news/botanix-pharmaceuticals-asxbot-evaluating-valuation-followin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-bot/botanix-pharmaceuticals-shares/news/botanix-pharmaceuticals-asxbot-evaluating-valuation-followin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK7502","BK7096","BK7508","BOT.AU"],"gpt_icon":0},{"id":"2577339406","title":"Did Sofdra Launch Progress and a Leadership Change Just Shift Botanix Pharmaceuticals' (ASX:BOT) Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2577339406","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577339406?lang=en_us&edition=fundamental","pubTime":"2025-10-22 05:13","pubTimestamp":1761081197,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals recently provided a comprehensive update on its quarterly activities and progress of the Sofdra® (sofpironium) topical gel launch, alongside announcing an executive change with Andrew Bickley becoming Joint Company Secretary ahead of Susan Park's departure at the end of October 2025.\nThe company's active participation in the 2025 Canaccord Genuity Drug & Device Conference and direct investor communication highlight an ongoing focus on product rollout and leadership...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-bot/botanix-pharmaceuticals-shares/news/did-sofdra-launch-progress-and-a-leadership-change-just-shif","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-bot/botanix-pharmaceuticals-shares/news/did-sofdra-launch-progress-and-a-leadership-change-just-shif","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PRGS","LU2065732104.USD","BK7096","BK7502","BK7508","BOT.AU","BK4097"],"gpt_icon":0},{"id":"2577455438","title":"Botanix Pharmaceuticals to Not Rely Upon ASX Partial Waiver After Verifying Sufficient Securities Under its Placement Capacity","url":"https://stock-news.laohu8.com/highlight/detail?id=2577455438","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577455438?lang=en_us&edition=fundamental","pubTime":"2025-10-21 14:12","pubTimestamp":1761027125,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals  said it would not rely upon a partial waiver granted by the ASX after it verified that the securities under its current placement capacity are sufficient to meet its obligations in relation to an earlier loan facility, according to a Tuesday Australian bourse filing.Botanix and its wholly-owned unit, Botanix Pharmaceuticals Inc., entered into documentation with Kreos Capital VII  and related entities for a loan facility of up to $30 million.The ASX had partially granted it a waiver of listing rules to allow the firm to seek shareholder approval at its annual general meeting for the ratification of the agreement to issue securities under the facility, so that those securities would not take up its placement capacity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["UK","BK4528","BK7096","BOT.AU","BK4205","BK7502","BK7508","BK4233"],"gpt_icon":0},{"id":"2576866058","title":"Botanix Pharmaceuticals Back On Track With Reduced Cash Burn, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2576866058","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576866058?lang=en_us&edition=fundamental","pubTime":"2025-10-20 10:45","pubTimestamp":1760928350,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals (ASX:BOT) is back on track following the release of its fiscal first quarter results, with reduced cash burn alleviating funding concerns, Euroz Hartleys said in a Monday note.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7096","BOT.AU","BK7502"],"gpt_icon":0},{"id":"2576012009","title":"Botanix Pharmaceuticals Q1 Net Revenue Hits $7.1 Million as Sofdra Prescriptions Jump 50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576012009","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576012009?lang=en_us&edition=fundamental","pubTime":"2025-10-20 06:28","pubTimestamp":1760912896,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals Ltd. reported that total prescriptions for Sofdra  grew 50% quarter over quarter to 20,418 in Q1 FY2026. Net revenue reached $7.1 million for the period. Operating cash outflow decreased 54% to $13.1 million compared to the previous quarter.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Botanix Pharmaceuticals Ltd. published the original content used to generate this news brief on October 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251019:nNDLbyvJNc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BOT.AU","BK7508","BK7502"],"gpt_icon":0},{"id":"2576500619","title":"Botanix Pharmaceuticals Ltd - Sofdra Net Revenue to a$7.1 Mln in Q1 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2576500619","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576500619?lang=en_us&edition=fundamental","pubTime":"2025-10-20 05:21","pubTimestamp":1760908919,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251019:nTUE3DZJYV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BOT.AU","BK7502","BK7096"],"gpt_icon":0},{"id":"2574487931","title":"While Botanix Pharmaceuticals (ASX:BOT) shareholders have made 123% in 3 years, increasing losses might now be front of mind as stock sheds 12% this week","url":"https://stock-news.laohu8.com/highlight/detail?id=2574487931","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574487931?lang=en_us&edition=fundamental","pubTime":"2025-10-11 06:37","pubTimestamp":1760135878,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals Limited ( ASX:BOT ) shareholders might be concerned after seeing the share price drop 12% in...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-bot/botanix-pharmaceuticals-shares/news/while-botanix-pharmaceuticals-asxbot-shareholders-have-made","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-bot/botanix-pharmaceuticals-shares/news/while-botanix-pharmaceuticals-asxbot-shareholders-have-made","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BOT.AU","BK7502","BK7508","BK7096"],"gpt_icon":0},{"id":"2573873639","title":"What a 40% Year Taught Us: 4 Lessons from the past 12 months (and 3 new stocks to buy)","url":"https://stock-news.laohu8.com/highlight/detail?id=2573873639","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573873639?lang=en_us&edition=fundamental","pubTime":"2025-10-07 09:12","pubTimestamp":1759799547,"startTime":"0","endTime":"0","summary":"This time last year, my co-PM Ben Richardsand I wrote this piece on Livewire, reflecting on the lessons learned in the first 12 months of running the Seneca Australian Small Companies Fund. The feedback was  positive, so we’ve decided to run it back with another candid review, this time of year 2.The 12 months to 30 September were exceptional.Our fund returned 39.16% after fees for the 12 months to 30 September 2025, outperforming the S&P/ASX Small Ordinaries Index by +17.66% — placing us among the top handful of Australian equity fund managers.Our fee structure remains straightforward and aligned: 0.00% management fee, with a 20% performance fee above the RBA Cash Rate, subject to a high watermark.With that in mind, what follows are four lessons from the past 12 months, each illustrated by a real case study from our portfolio. For every lesson learned, we’ll also share a new investment idea where we’re putting those insights into action for the year ahead.: 28% premium to last close (","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/what-a-40-year-taught-us-4-lessons-from-the-past-12-months-and-3-new-stocks-to-buy","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/what-a-40-year-taught-us-4-lessons-from-the-past-12-months-and-3-new-stocks-to-buy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["IOT","LU1917777945.USD","ERD.AU","BK7129","BK7062","BK7508","LU2023250504.SGD","LU2264538146.SGD","LU2106854487.HKD","RHI.AU","BK4149","LU1974910355.USD","CAT","LU0942090050.USD","BK7096","BK7100","BK7088","PNI.AU","MIN.AU","XKO.AU","LU0868494708.USD","QOR.AU","BK4585","BK4613","XJO.AU","IE00BSNM7G36.USD","EOL.AU","EHL.AU","XAO.AU","BK4520","D2O.AU","EZL.AU","BK7507","BK4516","BK7095","RUL.AU","BK7031","XRF.AU","CAT.AU","IFM.AU","RPL.AU","BK4588","BK4597","GQG.AU","LU1988902786.USD","PBH.AU","BK4532","BOT.AU","BK7024","BK7504"],"gpt_icon":0},{"id":"2569778093","title":"Botanix Pharmaceuticals' Sofdra Topical Gel Dermatologists' Preferred Option for Hyperhidrosis Treatment in Survey, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2569778093","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569778093?lang=en_us&edition=fundamental","pubTime":"2025-09-24 15:03","pubTimestamp":1758697395,"startTime":"0","endTime":"0","summary":"The efficacy and tolerability of Botanix Pharmaceuticals'  Sofdra topical gel was rated highly in a survey of US dermatologists conducted by Euroz Hartleys, and the dermatologists reported that Sofdra is their preferred first-line option for treatment of axillary hyperhidrosis, except where insurers require step edits, the investment firm said in a note on Wednesday.The survey involved in-depth interviews with five dermatologists who treated several hundred hyperhidrosis patients with the topical gel across different practice settings and regions of the US.Virtually all patients were able to secure treatment with Sofdra, including insurance coverage, out-of-pocket costs, and ease of obtaining the prescription. The dermatologists ranked access and safety as equally important, ahead of efficacy.Four of five dermatologists we interviewed said Sofdra changed how they manage hyperhidrosis, shifting from being reactive to proactive. Four of five dermatologists also observed some seasonality ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK7508","BOT.AU","BK7502"],"gpt_icon":0},{"id":"2569725971","title":"Hyperbot (BOT) has surged over 34% in the last 24 hours, currently trading at $0.175","url":"https://stock-news.laohu8.com/highlight/detail?id=2569725971","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569725971?lang=en_us&edition=fundamental","pubTime":"2025-09-24 10:03","pubTimestamp":1758679380,"startTime":"0","endTime":"0","summary":"BlockBeats News, September 24th, according to GMGN data, Hyperbot  surged over 34% in the past 24 hours, currently trading at $0.175, with a market capitalization of $175 million.Hyperbot is an AI-driven PerpDEX trading terminal used for on-chain contract data analysis, whale tracking, and intelligent mirror trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"theblockbeats_live","url":"https://www.theblockbeats.info//en/flash/313606","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/313606","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BK7096","BK7502","BK7508","BOT.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}]}}